# OnCo record nct07680790 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07680790/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07680790", "NCT07680790" ;
  schema:name "Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C"@en ;
  schema:description "A phase 3 trial of izalontamab brengitecan, osimertinib, pemetrexed, carboplatin and other drugs in lung cancer, run by Bristol-Myers Squibb, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07680790/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07680790> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/bms/> .